CATEGORY

Patient Recruitment

Beroe LiVE.Ai™

AI-powered self-service platform for all your sourcing decision needs across 1,600+ categories llike Patient Recruitment.

Market Data, Sourcing & Supplier Intelligence, and Price & Cost Benchmarking.

Schedule a Demo

Patient Recruitment Industry Benchmarks


Savings Achieved

(in %)

The average annual savings achieved in Patient Recruitment category is 8.17%

Payment Terms

(in days)

The industry average payment terms in Patient Recruitment category for the current quarter is 68.8 days

Compare your category performance against peers and industry benchmarks across 20+ parameters on Beroe LiVE.Ai™

Category Strategy and Flexibility

Engagement Model

Supply Assurance

Sourcing Process

Supplier Type

Pricing Model

Contract Length

SLAs/KPIs

Lead Time

Supplier Diversity

Targeted Savings

Risk Mitigation

Financial Risk

Sanctions

AMEs

Geopolitical Risk

Cost Optimization

Price per Unit Competitiveness

Specification Leanness

Minimum Order Quality

Payment Terms

Inventory Control

Meet Abi

The World’s first Digital Market Analyst

    Schedule a Demo
    Meet Abi

    The World’s first Digital Market Analyst

    Abi, the AI-powered digital assistant brings together data, insights, and intelligence for faster answers to sourcing questions

    Patient Recruitment Suppliers


    Patient Recruitment Supplier

    Find the right-fit patient recruitment supplier for your specific business needs and filter by location, industry, category, revenue, certifications, and more on Beroe LiVE.Ai™.

    Sample Supplier
    Company
    IQVIA HOLDINGS INC.
    Location
    Jackson, Mississipi
    Duns number
    3862211

    D&B SER Rating

    dnb logo

    Up to 3 months

    1 9
    4
    Low Risk High Risk

    The Supplier Evaluation Risk (SER) Rating is Dun & Bradstreet’s proprietary scoring system used to assess the probability that a business will seek relief from creditors or cease operations within the next 12 months. SER ratings range from 1 to 9, with 9 indicating the highest risk of failure. We’ve prepared an infographic to help business owners better understand what influences their SER Rating.

    Moody`s ESG Solution
    ESG Profile

    Company and Sector Performance
    36

    100
    Limited (1)
    ESG Perfomance (/100)
    Environment
    41
    Social
    30
    Governance
    43
    6 Domains Performance (/100)
    Business behaviour
    48
    Human rights
    39
    Community Environment
    31
    Corporate governance
    40
    Human resources
    22
    Security Scorecard
    77

    Threat indicators
    C
    75
    Network Security
    Detecting insecure network settings
    A
    100
    Hacker Chatter
    Monitoring hacker sites for chatter about your company
    D
    63
    DNS Health
    Detecting DNS insecure configuration and vulnerabilities
    C
    70
    Application Security
    Detecting common website application vulnerbilities
    C
    77
    Endpoint Security
    Detecting unprotected enpoints or entry points of user tools, such as desktops, laptops mobile devices, and virtual desktops
    A
    100
    Cubic Score
    Proprietary algorithms checking for implementation of common security best practices
    D
    60
    Patching Cadence
    Out of date company assets which may contain vulnerabilities of risk
    A
    100
    Social Engineering
    Measuring company awareness to a social engineering or phising attack
    A
    100
    IP Reputation
    Detecting suspecious activity, such as malware or spam, within your company network
    A
    100
    Information Leak
    Potentially confidential company information which may have been inadvertently leaked

    Industry Comparison
    iqvia.com
    Industry average
    Adverse Media Appearances
    Environmental Issues
    0
    Workforce Health Safety Issues
    0
    Product Service Issues
    1
    Human Rights Issues
    0
    Production Supply Chain Issues
    0
    Environmental Non Compliance Flags
    1
    Corruption Issues
    0
    Regulatory Non Compliance Flags
    2
    Fraud Issues
    0
    Labor Health Safety Flags
    0
    Regulatory Issues
    2
    Workforce Disputes
    0
    Sanctions
    0
    esg energy transition
    28
    Discrimination Workforce Rights Issues
    0
    esg controversies critical severity
    No

    Patient Recruitment market report transcript


    Patient Recruitment Global Market Outlook

    • The global demand is expected to be $8.2–8.6 Billion in 2021 and will grow at approx. 12—15 percent CAGR through 2020–2026

    • Focus on biologics, personalized medicine, and increasing complexity, in terms of protocol, study procedures, trial design, and globalization of clinical trials demanding regional regulatory compliance are the major factors driving the market

    • Availability of a large patient pool, coupled with cost-saving opportunity, due to reduced labor wage, is shifting the focus to the emerging nations

    • Large CROs have been continuously expanding their supply base through acquisitions and partnerships to provide integrated services

    • Of the site investigators, 52 percent expect a change in site models that is more inclusive of pharmacies and local or pop-up clinics

    Impact of COVID-19 on Patient Recruitment Industry

    • Implementation of patient-centric approaches and decentralized trials increased, owing to pandemic necessitating use of new technologies for trial success.

    • Diversity in clinical trials surfaced, owing to vaccine trials and now has become integral part of patient recruitment processes

    • Use of technologies, like eConsent/eCOA, ePRO, mobile devices, wearables, insertables, telemedicine has increased to enable DCT trials.

    • CROs are converting approx. 60 percent of their visits to remote monitoring

    • Approaches, like online recruitment, home nursing, and direct-to patient trial supply have been adopted to ensure patient safety and trial continuity

    • 75 percent of the organizations are in some stage of implementing virtual trials

    Procurement Centric Five Forces Analysis on Patient Recruitment Industry

    Suppliers–Established and emerging currently view large pharma as a key account. The attractiveness of a pharma client is high, as they bring in high purchase orders, good payment terms, and greater brand visibility. This acts as an enabler to move the accounts into a supplier's core business area.

    Supplier Power

    • Along with CROs and PROs suppliers in this industry comprises of hospitals and physicians, patient advocacy groups and focus groups, who directly communicate to the patients about the clinical trials. Patients are increasingly dependent on these means to enroll in clinical trials

    • Focus on rare disease and precision medicine have created more challenges to recruit patients and hence, digital players with access to wide patient data are gaining traction compared to traditional suppliers, thus keeping overall supplier power medium

    Barriers to New Entrants

    • Increased regulatory demand, varying regional regulatory compliance, as well as the cost associated with advertisement campaigns, database management, site management, clinical procedure and central lab make it more difficult for suppliers to pose competition to large suppliers

    • Advancement in AI and ML techniques has paved the way for new era of digital suppliers

    Intensity of Rivalry

    • The patient recruitment market is a highly fragmented market with CROs, PROs and niche players trying to gain market share

    • As the industry is trying to move towards digital trial recruitment, suppliers are trying to acquire tech oriented niche players to expand their capabilities in the digital field

    Threat of Substitutes

    • With the increase in adoption of Real world Evidence data, demand for supplier with access to advanced technology and access to patient data is increasing. Hence, suppliers focusing on newer tactics are emerging and posing competition to traditional players 

    • With the increase in PoCs, wearables and direct-to-patient initiatives, including patient communities voluntary trial selection by patients might be feasible

    • This will cause instability among the suppliers in the market

    Buyer Power

    • There is intense competition among sponsors to recruit appropriate quality patients on time

    • The supplier market is fragmented with multiple suppliers, who cater to several big pharmaceutical companies and provide a range of services associated with patient recruitment and retention

    • Pharma companies have a greater choice and ability to switch between suppliers, however, the intense demand for patients keeps the power moderate to high especially in rare therapeutic areas and oncology